Note: Biopta (Glasgow, UK and Maryland, USA) is now REPROCELL’s Center for predictive Drug Discovery.
Note: Reinnervate (Durham, UK) is now part of REPROCELL’s Center for predictive Drug Discovery.
On the REPROCELL blog
Latest
Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed
Overcome key challenges in clinical iPSC applications with REPROCELL's ethical sourcing, advanced reprogramming, and tailored solutions for reliable, scalable therapies.
12 May 2025
Epigenetic Modifications: Their Role in iPSC Reprogramming and Differentiation
Explore the critical role of epigenetic mechanisms like DNA methylation and histone modifications in iPSC reprogramming and differentiation. Learn how optimizing epigenetic stability enhances reprogramming efficiency, reduces variability, and ensures safer, more reliable iPSC applications for research and therapy.
02 May 2025
REPROCELL Connects with Maryland Governor Moore During His Japan Visit
Maryland Governor Moore strengthens biotech ties with Japan, highlighting REPROCELL's pivotal role in the Maryland-Kanagawa partnership during his trade mission.
22 April 2025
Exosomes from Stem Cells: iPSC vs. MSC-Derived Exosomes for Aesthetic and Regenerative Medicine
Discover how iPSC and MSC-derived exosomes revolutionize skin rejuvenation and anti-aging treatments in aesthetic medicine. Main Point Summary: The blog explores the potential of exosomes derived from induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) for skin rejuvenation and anti-aging treatments in aesthetic medicine, comparing their effectiveness, mechanisms, and applications.
14 April 2025
Can Stem Cells Revolutionize Sustainable Food Production?
Discover how stem cell technology is transforming sustainable food production, offering ethical and scalable alternatives to conventional meat, dairy, and seafood.
31 March 2025
.jpg?width=800&height=450&name=Biopta%20(Scottish%20Life%20Sciences).jpg)
